Jazz Pharmaceuticals and AbCellera Partner to Advance Next-Generation T-Cell Engaging Antibodies for Gastrointestinal and Solid Tumors
Jazz Pharmaceuticals and AbCellera have entered into a strategic research collaboration aimed at discovering and developing a new generation of T-cell engaging (TCE) multispecific antibodies for the treatment of gastrointestinal (GI) cancers and other solid tumors. The agreement combines Jazz’s growing oncology expertise with AbCellera’s advanced antibody discovery technologies, creating a partnership designed to accelerate the development of innovative immunotherapies for patients facing difficult-to-treat cancers.
The collaboration reflects the increasing interest across the biopharmaceutical industry in harnessing the immune system to target cancer more effectively. T-cell engaging therapies have emerged as one of the most promising approaches in oncology, offering the potential to direct a patient’s immune cells toward tumor cells with greater precision. Through this partnership, the two companies aim to develop novel multispecific antibodies capable of overcoming challenges associated with treating solid tumors, an area where many current immunotherapy approaches have faced limitations.
Expanding Jazz Pharmaceuticals’ Oncology Strategy
The agreement represents another important step in Jazz Pharmaceuticals’ efforts to strengthen and diversify its oncology portfolio. Over recent years, the company has expanded beyond its historical focus areas, investing heavily in innovative cancer therapies and building a pipeline designed to address significant unmet medical needs.
According to Josh Allen, Ph.D., Chief Scientific Officer, Oncology at Jazz Pharmaceuticals, the collaboration aligns closely with the company’s strategic priorities. He noted that the partnership supports Jazz’s broader oncology ambitions while expanding its focus in gastrointestinal cancers, an area where substantial unmet patient needs remain.
Allen emphasized that the collaboration will allow Jazz to leverage AbCellera’s specialized expertise in antibody discovery and T-cell engager technology to identify potentially best-in-class multispecific antibodies. The ultimate goal is to advance promising candidates into clinical development and deliver meaningful therapeutic innovations for patients battling GI cancers and other solid tumors.
Gastrointestinal cancers remain among the leading causes of cancer-related deaths worldwide. Despite advancements in surgery, chemotherapy, targeted therapies, and immunotherapy, many patients continue to experience poor outcomes, particularly in advanced or metastatic disease settings. This reality has fueled growing interest in novel therapeutic approaches capable of improving treatment effectiveness while minimizing toxicity.
Through the collaboration, Jazz seeks to broaden its presence in this important therapeutic area and position itself at the forefront of next-generation immuno-oncology innovation.
Leveraging AbCellera’s T-Cell Engager Platform
A central component of the partnership is AbCellera’s proprietary T-cell engager platform, which has been developed specifically to support the discovery and advancement of multispecific antibodies for difficult-to-treat cancers.
AbCellera has built a fully integrated platform that spans the entire development process, from antibody discovery and engineering through clinical manufacturing capabilities. The company’s technology combines advanced computational methods, high-throughput screening systems, protein engineering expertise, and sophisticated biological assays to identify and optimize therapeutic antibody candidates.
The platform includes several proprietary components designed to enhance T-cell engager development. Among these are novel CD3-binding antibody panels, which play a critical role in recruiting T cells to attack cancer cells. The platform also incorporates costimulatory targeting arms intended to enhance immune activation and improve therapeutic responses.
Additionally, AbCellera has developed multispecific protein engineering technologies that enable the creation of antibodies capable of binding multiple targets simultaneously. These sophisticated molecular designs may help improve tumor targeting, enhance anti-cancer activity, and potentially reduce off-target effects.
Supporting these capabilities is a suite of high-throughput functional assays that allow researchers to rapidly evaluate antibody performance and identify candidates with the most favorable characteristics for clinical development.
By integrating these technologies into a unified discovery engine, AbCellera aims to accelerate the identification of optimized development candidates while increasing the probability of clinical success.
Growing Interest in T-Cell Engaging Therapies
T-cell engagers have become one of the most exciting areas in cancer drug development. Unlike traditional therapies that directly attack tumor cells, T-cell engagers are designed to recruit and activate a patient’s immune system to recognize and destroy cancer.
These therapies typically work by binding simultaneously to cancer cells and T cells, bringing the immune cells into close proximity with tumors. This interaction can trigger targeted immune responses and promote tumor cell destruction.
Several T-cell engager therapies have already demonstrated significant clinical benefits in certain blood cancers, leading to increased investment in the field. However, translating similar success to solid tumors has proven more challenging due to factors such as tumor heterogeneity, immunosuppressive tumor microenvironments, and difficulties achieving sufficient immune cell infiltration.
Researchers believe multispecific antibody technologies may help address some of these obstacles. By incorporating multiple targeting mechanisms into a single molecule, next-generation T-cell engagers may offer enhanced specificity, stronger immune activation, and improved therapeutic efficacy.
Carl Hansen, Ph.D., founder and Chief Executive Officer of AbCellera, highlighted the company’s extensive experience in developing T-cell engager technologies and expressed enthusiasm about partnering with Jazz Pharmaceuticals.
Hansen noted that T-cell engagers are capable of driving highly targeted immune activation and may significantly improve treatment outcomes compared with existing therapeutic approaches in GI cancers and other solid tumors. He added that the collaboration provides an opportunity to combine AbCellera’s differentiated technology platform with Jazz’s development expertise to advance novel cancer therapies for patients with limited treatment options.
Structure of the Collaboration
The agreement establishes a multi-program research collaboration beginning with two initial discovery programs focused on identifying novel T-cell engaging multispecific antibodies. In addition, the companies have committed to launching a third discovery program within the next twelve months.
Under the terms of the arrangement, AbCellera will lead discovery and early-stage research activities for each program. This work will involve identifying therapeutic candidates, optimizing antibody designs, and generating data necessary to support future development decisions.
For each research program, Jazz will receive an option to assume responsibility for subsequent development and commercialization activities. If Jazz chooses to exercise its option and pays the applicable option fee, the company will obtain exclusive worldwide rights to develop, manufacture, and commercialize products arising from that program.
This structure allows Jazz to evaluate emerging data from the research efforts before committing additional resources to clinical development while providing AbCellera with significant opportunities to participate in the long-term success of resulting therapies.
Financial Terms and Potential Milestones
The collaboration includes substantial financial commitments that underscore both companies’ confidence in the potential of the partnership.
AbCellera will receive total upfront payments of $56 million covering the first two research programs. An additional $28 million payment will be made upon initiation of the third discovery program, bringing the total near-term value of the collaboration to $84 million.
Beyond these initial payments, AbCellera stands to receive significant future compensation if development programs advance successfully. For each program in which Jazz exercises its option, AbCellera may earn up to $792 million through a combination of option fees and development, regulatory, and commercial milestone payments.
These milestone opportunities are tied to key achievements across the product development lifecycle, including clinical progress, regulatory approvals, and commercial performance.
In addition to milestone payments, AbCellera will be eligible to receive tiered royalties on future net sales of any commercialized products. Royalty rates are structured to range from the mid-single digits to the low double digits, allowing the company to participate in long-term commercial success should therapies resulting from the collaboration reach the market.
The agreement also provides flexibility for future expansion. Jazz and AbCellera may mutually agree to initiate up to two additional research programs beyond the initial three. Furthermore, the companies can choose to extend AbCellera’s involvement into later development stages, including investigational new drug (IND)-enabling studies and the manufacturing of clinical trial material.
Advancing the Future of Cancer Immunotherapy
The partnership between Jazz Pharmaceuticals and AbCellera highlights the growing momentum behind next-generation immunotherapy approaches and the increasing importance of strategic collaborations in biotechnology innovation.
By combining Jazz’s oncology development capabilities with AbCellera’s advanced antibody discovery platform, the companies aim to accelerate the creation of novel T-cell engaging therapies capable of addressing some of the most challenging cancers. The focus on gastrointestinal malignancies and other solid tumors reflects an area of substantial unmet medical need, where innovative treatment options could have a profound impact on patient outcomes.
As the collaboration progresses, both organizations will seek to translate cutting-edge antibody engineering and immune-targeting technologies into new therapeutic candidates that may ultimately redefine treatment possibilities for patients with hard-to-treat cancers worldwide.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders.
Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.
